Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone
Cæcilie Leding(Copenhagen University Hospital), Thomas Benfield(University of Copenhagen), Simone Bastrup Israelsen(Copenhagen University Hospital), Marie Helleberg(Rigshospitalet), Lars Haukali Omland(Copenhagen University Hospital), Rajesh Mohey(Regionshospitalet Herning), Claire Holm(Frederiksberg Hospital), Christian Niels Meyer(UniQure (Netherlands)), Ole Kirk(University of Copenhagen), Işık Somuncu Johansen, Christian Brieghel(Copenhagen University Hospital), Zitta Barrella Harboe(Statens Serum Institut), Jonathan Starling(Copenhagen University Hospital), Tomas Ø. Jensen(Copenhagen University Hospital), Ole S. Søgaard(Aarhus University Hospital), Torben Tranborg(Bispebjerg Hospital), Lars Pedersen(Bispebjerg Hospital), Birgitte Lindegaard(University of Copenhagen), Stine Johnsen(Harvard University), Christian Søborg(Gentofte Hospital), Henrik Nielsen(Aalborg University Hospital), Merete Storgaard(Aarhus University Hospital), Stig Lønberg Nielsen(University of Southern Denmark), Jacob Bodilsen(Aalborg University Hospital), Pernille Ravn(Herlev Hospital), Daria Podlekareva(University of Copenhagen), Hanne Rolighed Christensen(Frederiksberg Hospital), Lothar Wiese(Zealand University Hospital), Janne Jensen(Kolding Hospital), Signe Heide Westring Worm(Gentofte Hospital)
Cited by 7
Related Papers
Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
|The Lancet|2014|930
One Biocatalyst–Many Applications: The Use of Candida Antarctica B-Lipase in Organic Synthesis
|Biocatalysis and Biotransformation|1998|682